Immunovant Inc (IMVT) Stock Price, Quote & News

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 580 3099

Website: immunovant.com

Address:

320 West 37th Street, 6th Floor, New York, United States

RonIsWrong Nov. 14 at 3:54 PM

$IMVT 👀👀

0 · Reply

SpaceCityKid Nov. 12 at 2:19 PM

$IMVT In a beautiful falling flag. It's getting ready to rip

0 · Reply

USA_toinfinity_andbeyond Nov. 11 at 12:42 PM

$IMVT "Immunovant stock rating reiterated by Oppenheimer, cites progress in autoimmune portfolio" Price target $ 54. https://www.investing.com/news/analyst-ratings/immunovant-stock-rating-reiterated-by-oppenheimer-cites-progress-in-autoimmune-portfolio-93CH-4348781

0 · Reply

d_risk Nov. 10 at 4:12 PM

$IMVT - Immunovant Inc. Common Stock - 10Q - Updated Risk Factors IMVT flags heightened risk from dependence on HanAll license for core IP; loss or breach could seriously impact operations. #Biotechnology #Pharmaceutical #OperationalRisk #LicenseDependency #IntellectualPropertyRisk 🟢 Added 🟠 Removed https://d-risk.ai/IMVT/10-Q/2025-11-10

0 · Reply

Pika_Capital Nov. 10 at 3:07 PM

$IMVT my best idea for 2026 probably. Buy this nonsense dip

0 · Reply

OpenOutcrier Nov. 10 at 2:03 PM

$IMVT (-10.1% pre) Immunovant, Inc. (IMVT) Misses Q2 EPS by 2c https://ooc.bz/l/83910

0 · Reply

USA_toinfinity_andbeyond Nov. 4 at 11:35 PM

$IMVT 📈🆙️🇺🇸💯

0 · Reply

lakeswim951 Nov. 4 at 11:20 PM

$IMVT Anyone have visibility of after hours trades? Strange candle on thinkorswim but looks like decent volume so

0 · Reply

RonIsWrong Nov. 4 at 3:40 PM

$IMVT 👀👀

0 · Reply

Cyrus_C Nov. 3 at 10:43 AM

$IMVT very quiet, looks like its mostly tutes and very few retail here

0 · Reply

Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 7:00 AM EST - 6 days ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Oct 27, 2025, 4:10 PM EDT - 20 days ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

ROIV

Sep 3, 2025, 12:57 PM EDT - 2 months ago

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Aug 27, 2025, 8:33 PM EDT - 2 months ago

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

Aug 11, 2025, 7:00 AM EDT - 3 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

May 29, 2025, 7:00 AM EDT - 6 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

Mar 19, 2025, 5:07 PM EDT - 8 months ago

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward

Mar 19, 2025, 7:59 AM EDT - 8 months ago

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Mar 19, 2025, 7:45 AM EDT - 8 months ago

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025, 4:32 PM EDT - 8 months ago

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Feb 6, 2025, 6:30 AM EST - 10 months ago

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Jan 24, 2025, 1:34 PM EST - 10 months ago

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Dec 27, 2024, 10:50 AM EST - 11 months ago

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Dec 11, 2024, 6:25 AM EST - 1 year ago

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Sep 9, 2024, 9:12 AM EDT - 1 year ago

Top 2 Health Care Stocks That May Collapse This Quarter

TERN

Sep 9, 2024, 3:55 AM EDT - 1 year ago

Immunovant Provides Update on Graves' Disease Development Program

Sep 5, 2024, 6:30 AM EDT - 1 year ago

Immunovant to Host Graves' Disease Program Update on September 9, 2024

Aug 6, 2024, 8:25 AM EDT - 1 year ago

Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging

FIP FTAI OABI PRPL REAL RICK

May 29, 2024, 4:01 PM EDT - 1 year ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Apr 4, 2024, 2:12 AM EDT - 1 year ago

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Mar 12, 2024, 7:30 AM EDT - 1 year ago

Immunovant Awarded U.S. Patent for IMVT-1402

Feb 12, 2024, 7:00 AM EST - 1 year ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Jan 9, 2024, 9:00 AM EST - 2 years ago

Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas

BUR LQDA

Jan 3, 2024, 8:00 AM EST - 2 years ago

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 4:30 PM EST - 2 years ago

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Dec 14, 2023, 1:24 PM EST - 2 years ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH PRVA RCKT

Nov 28, 2023, 7:00 AM EST - 2 years ago

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Nov 14, 2023, 3:48 AM EST - 2 years ago

Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena

Nov 13, 2023, 8:00 AM EST - 2 years ago

Immunovant to Present at Upcoming Investor Conferences

Nov 9, 2023, 7:00 AM EST - 2 years ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Oct 2, 2023, 4:52 PM EDT - 2 years ago

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 27, 2023, 11:41 PM EDT - 2 years ago

Immunovant Announces Pricing of $450 Million Common Stock Financing

Sep 27, 2023, 5:30 AM EDT - 2 years ago

Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock

Sep 26, 2023, 5:00 PM EDT - 2 years ago

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Sep 26, 2023, 4:20 PM EDT - 2 years ago

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

Sep 26, 2023, 11:10 AM EDT - 2 years ago

Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)

Sep 26, 2023, 7:57 AM EDT - 2 years ago

Immunovant shares surge after antibody treatment succeeds in early-stage study

Sep 26, 2023, 6:00 AM EDT - 2 years ago

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Sep 25, 2023, 11:01 PM EDT - 2 years ago

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

Jul 19, 2023, 5:50 PM EDT - 2 years ago

Immunovant Stock: With Anti-FcRn Validation Continuing, This Is A Must-Watch

May 24, 2023, 1:14 PM EDT - 2 years ago

Immunovant Could Be Poised For A Breakout In H2 2023

May 22, 2023, 7:00 AM EDT - 2 years ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

Feb 3, 2023, 7:00 AM EST - 3 years ago

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

RonIsWrong Nov. 14 at 3:54 PM

$IMVT 👀👀

0 · Reply

SpaceCityKid Nov. 12 at 2:19 PM

$IMVT In a beautiful falling flag. It's getting ready to rip

0 · Reply

USA_toinfinity_andbeyond Nov. 11 at 12:42 PM

0 · Reply

d_risk Nov. 10 at 4:12 PM

0 · Reply

Pika_Capital Nov. 10 at 3:07 PM

$IMVT my best idea for 2026 probably. Buy this nonsense dip

0 · Reply

OpenOutcrier Nov. 10 at 2:03 PM

$IMVT (-10.1% pre) Immunovant, Inc. (IMVT) Misses Q2 EPS by 2c https://ooc.bz/l/83910

0 · Reply

USA_toinfinity_andbeyond Nov. 4 at 11:35 PM

$IMVT 📈🆙️🇺🇸💯

0 · Reply

lakeswim951 Nov. 4 at 11:20 PM

$IMVT Anyone have visibility of after hours trades? Strange candle on thinkorswim but looks like decent volume so

0 · Reply

RonIsWrong Nov. 4 at 3:40 PM

$IMVT 👀👀

0 · Reply

Cyrus_C Nov. 3 at 10:43 AM

$IMVT very quiet, looks like its mostly tutes and very few retail here

0 · Reply

SqueezeChronometer Nov. 2 at 11:56 AM

Next major retail squeeze candidate right here $CRSR $MFH $PGEN $IMVT ,

0 · Reply

Quantum_Capital_LLC Oct. 31 at 2:46 PM

$IMVT do your DD. Currently I am at +40% return and I am expecting a bigger return soon.

0 · Reply

lakeswim951 Oct. 30 at 5:29 PM

$ROIV $IMVT Wish I knew what was going on with these 2 beauties

3 · Reply

RonIsWrong Oct. 30 at 2:25 PM

$IMVT Watching Immunovant; Shares Moving Higher, Traders Circulate Unconfirmed Rumor Co Mentioned By M&A Blog

0 · Reply

Tdorsey1776 Oct. 30 at 2:20 PM

$IMVT "There's speculation that Immunovant has attracted takeover interest, according to traders, who cited a Betaville "uncooked" alert that was circulating on Thursday. One of the companies interested in buying Immunovant is Roivant (ROIV), Immunovant's largest shareholder."

0 · Reply

USA_toinfinity_andbeyond Oct. 30 at 2:14 PM

$IMVT There's a lot more coming. The bullish scenario is around 55 bucks by January.

0 · Reply

Pika_Capital Oct. 30 at 2:08 PM

$IMVT if you listened to pika you would have been +60% ;)

0 · Reply

ChessGM Oct. 30 at 2:05 PM

$IMVT May I say: "potential buyout?". Very rare that stock is jumping 15% without any news. $IMVT volume is on track to exceed 90 day average volume...

0 · Reply

Tdorsey1776 Oct. 30 at 2:02 PM

$IMVT Truist with egg on their face....silly PT of $16. The IB agendas will destroy retail if you let them.

0 · Reply

Pika_Capital Oct. 30 at 1:52 PM

$IMVT everyone hated it at $15. It's funny how sentiment can change in a month

0 · Reply

USA_toinfinity_andbeyond Oct. 29 at 5:57 PM

$IMVT I just bought more shares. Super bullish💯📈💲🇺🇸🚀

0 · Reply

BestNwest Oct. 28 at 6:02 AM

$IMVT price target 60$ next year

1 · Reply

Market Cap	4.16B
Revenue (ttm)	0.00
Net Income (ttm)	-413.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,559,200
Avg Vol	1,840,264
Day's Range	N/A - N/A
Shares Out	175.28M
Stochastic %K	68%
Beta	0.60
Analysts	Strong Sell
Price Target	$38.73